85 related articles for article (PubMed ID: 22349050)
1. Developability assessment of clinical drug products with maximum absorbable doses.
Ding X; Rose JP; Van Gelder J
Int J Pharm; 2012 May; 427(2):260-9. PubMed ID: 22349050
[TBL] [Abstract][Full Text] [Related]
2. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
3. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
[TBL] [Abstract][Full Text] [Related]
4. Identification of suitable formulations for high dose oral studies in rats using in vitro solubility measurements, the maximum absorbable dose model, and historical data sets.
Wuelfing WP; Kwong E; Higgins J
Mol Pharm; 2012 May; 9(5):1163-74. PubMed ID: 22394323
[TBL] [Abstract][Full Text] [Related]
5. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
Wei H; Löbenberg R
Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
[TBL] [Abstract][Full Text] [Related]
6. Applications of physiologically based absorption models in drug discovery and development.
Parrott N; Lave T
Mol Pharm; 2008; 5(5):760-75. PubMed ID: 18547054
[TBL] [Abstract][Full Text] [Related]
7. Use of (1)H NMR to facilitate solubility measurement for drug discovery compounds.
Lin M; Tesconi M; Tischler M
Int J Pharm; 2009 Mar; 369(1-2):47-52. PubMed ID: 19073245
[TBL] [Abstract][Full Text] [Related]
8. Prediction of human pharmacokinetics--gastrointestinal absorption.
Fagerholm U
J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
[TBL] [Abstract][Full Text] [Related]
9. Fraction of a dose absorbed estimation for structurally diverse low solubility compounds.
Sugano K
Int J Pharm; 2011 Feb; 405(1-2):79-89. PubMed ID: 21134428
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
11. Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect.
Sugano K
Int J Pharm; 2010 Mar; 387(1-2):103-9. PubMed ID: 20006692
[TBL] [Abstract][Full Text] [Related]
12. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models.
Dokoumetzidis A; Kalantzi L; Fotaki N
Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):491-505. PubMed ID: 17696801
[TBL] [Abstract][Full Text] [Related]
13. Applications of high-throughput ADME in drug discovery.
Kassel DB
Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
[TBL] [Abstract][Full Text] [Related]
14. A physiological model for the estimation of the fraction dose absorbed in humans.
Willmann S; Schmitt W; Keldenich J; Lippert J; Dressman JB
J Med Chem; 2004 Jul; 47(16):4022-31. PubMed ID: 15267240
[TBL] [Abstract][Full Text] [Related]
15. Computational oral absorption simulation of free base drugs.
Sugano K
Int J Pharm; 2010 Oct; 398(1-2):73-82. PubMed ID: 20655999
[TBL] [Abstract][Full Text] [Related]
16. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
[TBL] [Abstract][Full Text] [Related]
17. The composite solubility versus pH profile and its role in intestinal absorption prediction.
Hendriksen BA; Felix MV; Bolger MB
AAPS PharmSci; 2003; 5(1):E4. PubMed ID: 12713276
[TBL] [Abstract][Full Text] [Related]
18. Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species.
Wuelfing WP; Daublain P; Kesisoglou F; Templeton A; McGregor C
Mol Pharm; 2015 Apr; 12(4):1031-9. PubMed ID: 25671350
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
20. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
